Immunogenicity and Potential for Intraocular Inflammation of Intravitreal Anti-VEGF Drugs

IF 1.6 Q3 MEDICINE, RESEARCH & EXPERIMENTAL Current Therapeutic Research-clinical and Experimental Pub Date : 2024-01-01 DOI:10.1016/j.curtheres.2024.100742

Hyeong Min Kim MD, MSc , Se Joon Woo MD, PhD

{"title":"Immunogenicity and Potential for Intraocular Inflammation of Intravitreal Anti-VEGF Drugs","authors":"Hyeong Min Kim MD, MSc , Se Joon Woo MD, PhD","doi":"10.1016/j.curtheres.2024.100742","DOIUrl":null,"url":null,"abstract":"<div><h3>Background</h3><p>Concerns of intraocular inflammation associated with intravitreal administration of anti-VEGF drugs have been risen and the exact mechanism is not yet elucidated.</p></div><div><h3>Objective</h3><p>To explore the relationship between immunogenicity and intraocular inflammation in intravitreal anti-VEGF drugs.</p></div><div><h3>Methods</h3><p>This review examines the immunogenicity of individual intravitreal anti-VEGF drugs and their potential link to intraocular inflammation.</p></div><div><h3>Results</h3><p>We suggest that the main cause of intraocular inflammation is the presence of pre-existing and treatment-induced antidrug antibodies, along with considerations related to the molecular structure, which includes the drug's format and size.</p></div><div><h3>Conclusions</h3><p>Researchers and clinicians involved in the advancement of new anti-VEGF drugs should take into consideration the factors related to intraocular inflammation that have been discussed.</p></div>","PeriodicalId":10920,"journal":{"name":"Current Therapeutic Research-clinical and Experimental","volume":"100 ","pages":"Article 100742"},"PeriodicalIF":1.6000,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S0011393X24000122/pdfft?md5=726046823de302fc9e832324390aa5ae&pid=1-s2.0-S0011393X24000122-main.pdf","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Current Therapeutic Research-clinical and Experimental","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0011393X24000122","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"MEDICINE, RESEARCH & EXPERIMENTAL","Score":null,"Total":0}

引用次数: 0

Abstract

Background

Concerns of intraocular inflammation associated with intravitreal administration of anti-VEGF drugs have been risen and the exact mechanism is not yet elucidated.

Objective

To explore the relationship between immunogenicity and intraocular inflammation in intravitreal anti-VEGF drugs.

Methods

This review examines the immunogenicity of individual intravitreal anti-VEGF drugs and their potential link to intraocular inflammation.

Results

We suggest that the main cause of intraocular inflammation is the presence of pre-existing and treatment-induced antidrug antibodies, along with considerations related to the molecular structure, which includes the drug's format and size.

Conclusions

Researchers and clinicians involved in the advancement of new anti-VEGF drugs should take into consideration the factors related to intraocular inflammation that have been discussed.

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

玻璃体内抗血管内皮生长因子药物的免疫原性和眼内炎症的可能性

目的探讨玻璃体内抗血管内皮生长因子药物的免疫原性与眼内炎症之间的关系。方法本综述研究了个别玻璃体内抗血管内皮生长因子药物的免疫原性及其与眼内炎症的潜在联系。结果我们认为，眼内炎症的主要原因是已有的和治疗诱导的抗药物抗体的存在，以及与分子结构有关的考虑因素，包括药物的形式和大小。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

Current Therapeutic Research-clinical and Experimental 医学-药学

CiteScore

3.50

自引率

0.00%

发文量

审稿时长

3 months

期刊介绍： We also encourage the submission of manuscripts presenting preclinical and very preliminary research that may stimulate further investigation of potentially relevant findings, as well as in-depth review articles on specific therapies or disease states, and applied health delivery or pharmacoeconomics. CTR encourages and supports the submission of manuscripts describing: • Interventions designed to understand or improve human health, disease treatment or disease prevention; • Studies that focus on problems that are uncommon in resource-rich countries; • Research that is "under-published" because of limited access to monetary resources such as English language support and Open Access fees (CTR offers deeply discounted English language editing); • Republication of articles previously published in non-English journals (eg, evidence-based guidelines) which could be useful if translated into English; • Preclinical and clinical product development studies that are not pursued for further investigation based upon early phase results.